UTA.09703.HCMJp
TAUi001-A
General
Cell Line |
|
| hPSCreg name | TAUi001-A |
| Cite as: | TAUi001-A (RRID:CVCL_ZA77) |
| Alternative name(s) |
UTA.09703.HCMJp
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi035-A (NP0139-A, NP0139-3E) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy UKKi035-B (NP0139-B, NP0139-6C) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy UKKi035-C (NP0139-C, NP0139-24D) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy |
| Last update | 19th April 2022 |
| User feedback | |
Provider |
|
| Generator | Tampere University (TAU) |
| Derivation country | Finland |
External Databases |
|
| BioSamples | SAMEA6880673 |
| Cellosaurus | CVCL_ZA77 |
| Wikidata | Q98133169 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Fit4purpose-OOC project
Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
| Subclones | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA6880674 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Committee of Pirkanmaa Hospital District |
| Approval number | R08070 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type | |
| Collected in | 2012 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||||||||
| Feeder cells |
CF-1 MEF MITC Cellfinder Ont Id: CELDA_00007731 |
||||||||||||||||||
| Passage method |
Enzymatically
Collagenase
|
||||||||||||||||||
| CO2 Concentration | 5 % | ||||||||||||||||||
| Medium |
Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| NANOG |
Yes |
|||||
| ZFP42 (REX-1) |
Yes |
|||||
| c-MYC |
Yes |
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| KDR |
Yes |
| ACTC1 - alpha cardiac actinin |
Yes |
Protocol or reference
eb 09703.HCMJp.jpg
EB-PCR
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.